Results 61 to 70 of about 1,901 (143)

Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil

open access: yesDrug Design, Development and Therapy, 2017
Sheng Zhu, Yu-Hui Yang, Rong-Wei Gao, Ran Li, Yu-Zhen Zou, Lei Feng, Bo Zhang Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
Zhu S   +6 more
doaj  

Treatment of chronic hepatitis B

open access: yesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2012
<p style="text-justify: inter-ideograph; text-align: justify;"><strong>Background and objectives:</strong>The primary goal of therapy in patients with chronic hepatitis B is durable suppression of HBV DNA to the lowest possible level ...
G Montazeri
doaj  

Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Na?ve Chronic Hepatitis B Patients at 48 Weeks

open access: yesGut and Liver, 2011
Background/AimsTo reveal possible factors predicting the effect of adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and optimize the utilization of ADV.Methods : In total, 168 treatment-na?ve CHB patients were enrolled, including 117 ...
doaj   +1 more source

Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B. [PDF]

open access: yesBiomed Rep, 2021
Sano T   +8 more
europepmc   +1 more source

Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient

open access: yesGut and Liver, 2010
Adefovir dipivoxil (ADV) is commonly used as an antiviral agent in the treatment of chronic hepatitis B or human immunodeficiency virus infection. Nephrotoxicity has been shown to occur at daily dosages of 60-120 mg.
doaj   +1 more source

Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation. [PDF]

open access: yesFront Immunol, 2020
Voss L   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy